Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.25 USD 3.21% Market Closed
Market Cap: 598.8m USD
Have any thoughts about
Autolus Therapeutics PLC?
Write Note

Autolus Therapeutics PLC
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Autolus Therapeutics PLC
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Autolus Therapeutics PLC
NASDAQ:AUTL
Total Current Assets
$275.3m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Total Current Assets
$315.1m
CAGR 3-Years
204%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Total Current Assets
ÂŁ404.9m
CAGR 3-Years
63%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Total Current Assets
$966.2m
CAGR 3-Years
52%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Total Current Assets
ÂŁ528.8m
CAGR 3-Years
51%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Total Current Assets
ÂŁ271.1m
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
5%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
598.8m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
5.07 USD
Undervaluation 56%
Intrinsic Value
Price

See Also

What is Autolus Therapeutics PLC's Total Current Assets?
Total Current Assets
275.3m USD

Based on the financial report for Dec 31, 2023, Autolus Therapeutics PLC's Total Current Assets amounts to 275.3m USD.

What is Autolus Therapeutics PLC's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
12%

Over the last year, the Total Current Assets growth was -35%. The average annual Total Current Assets growth rates for Autolus Therapeutics PLC have been 12% over the past three years .

Back to Top